


2017 COCHLEAR LIMITED

Notice of Annual General Meeting



Notice of Annual General Meeting



Notice is hereby given that the Annual General Meeting of the members of Cochlear Limited (the Company or Cochlear) will be held at the Australian Securities Exchange, Exchange Square Auditorium, 20 Bridge Street, Sydney NSW 2000 on Tuesday 17 October 2017 at 10:00am (AEDT).

Business of the meeting

Ordinary business

1. Financial and other reports

To receive and consider the Company's Financial Report, the Directors' Report and the Auditor's Report in respect of the financial year ended 30 June 2017 and to consider and, if thought fit, to pass the following resolution:

1.1 "THAT the Company's Financial Report, the Directors' Report and the Auditor's Report in respect of the financial year ended 30 June 2017 be received."

Note: An explanation of the proposed resolution is set out at Item 1 of the Explanatory Notes attached to this Notice of Annual General Meeting.

2. Remuneration Report

To consider and, if thought fit, to pass the following non-binding resolution:

2.1 "THAT the Company's Remuneration Report in respect of the financial year ended 30 June 2017 be adopted."

Voting Exclusion Statement: In accordance with the Corporations Act 2001 (Cth), no votes can be cast by or on behalf of a member of key management personnel (KMP) whose remuneration details are included in the Remuneration Report and their closely related parties (collectively referred to as a Prohibited Voter). However, a Prohibited Voter may: (a) vote directed proxies for someone other than a Prohibited Voter; and (b) vote undirected proxies for someone other than a Prohibited Voter if the Prohibited Voter who is voting is the Chair of the meeting and the proxy/voting form: (i) does not specify the way the proxy is to vote on the resolution; and (ii) expressly authorises the Chair to exercise the proxy even if the resolution is connected directly or indirectly with the remuneration of a Prohibited Voter. If you intend to appoint the Chair as your proxy and you do not want your vote exercised in favour of this resolution, you should direct the Chair to vote against, or to abstain from voting on, this resolution.

Note: An explanation of the proposed resolution is set out at Item 2 of the Explanatory Notes attached to this Notice of Annual General Meeting.

3. Re-election of directors

To consider and, if thought fit, to pass the following resolutions as ordinary resolutions:

3.1 "THAT Mr Andrew Denver, being a director who is retiring in accordance with the Company's Constitution and who, being eligible, offers himself for re-election as a director of the Company, be re-elected as a director of the Company."

3.2 "THAT Mr Rick Holliday-Smith, being a director who is retiring in accordance with the Company's Constitution and who, being eligible, offers himself for re-election as a director of the Company, be re-elected as a director of the Company."

3.3 "THAT Prof Bruce Robinson, AM, being a director who is retiring in accordance with the Company's Constitution (this being the first Annual General Meeting of the Company since his appointment by the directors) and who, being eligible, offers himself for re-election as a director of the Company, be re-elected as a director of the Company."

Note: An explanation of the proposed resolutions is set out at Item 3 of the Explanatory Notes attached to this Notice of Annual General Meeting.

Special business

4. Approval of securities to be granted to the President under the Cochlear Executive Incentive Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

4.1 "THAT approval be given to:

(a) the grant to Mr Dig Howitt, the Company's President, of options and performance rights under the Cochlear Executive Incentive Plan calculated in accordance with the formula and on the terms summarised in the Explanatory Notes attached to the Notice of Annual General Meeting; and

(b) the transfer to Mr Howitt of existing shares upon the exercise of any options and/or performance rights granted to Mr Howitt pursuant to (a) above."

Notice of Annual General Meeting

Hear now. And always



Voting Exclusion Statement: In accordance with the Corporations Act 2001 (Cth), a member of KMP and their closely related parties may not vote as a proxy on this resolution if the appointment does not specify how the proxy is to vote. However, the Chair of the meeting can vote undirected proxies, provided the proxy/voting form expressly authorises the Chair to do so.

Note: An explanation of the proposed resolution is set out at Item 4 of the Explanatory Notes attached to this Notice of Annual General Meeting.

5. Approval to increase the maximum aggregate remuneration of non-executive directors

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

5.1 "THAT the aggregate maximum sum available for remuneration of non-executive directors is increased by \$500,000 per financial year to \$3,000,000 per financial year."

Voting Exclusion Statement: In accordance with the Australian Securities Exchange (ASX) Listing Rules, the Company will disregard any votes cast on this resolution: (a) by a director of the Company; and/or (b) by any associate of a director of the Company. In accordance with the ASX Listing Rules, the Company need not disregard any such vote if: (a) it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy/voting form; or (b) it is cast by a person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy/voting form to vote as the proxy decides. Further, in accordance with the Corporations Act 2001 (Cth), a member of KMP and their closely related parties may not vote as a proxy on this resolution if the appointment does not specify how the proxy is to vote. However, the Chair of the meeting can vote undirected proxies, provided the proxy/voting form expressly authorises the Chair to do so.

Note: An explanation of the proposed resolution is set out at Item 5 of the Explanatory Notes attached to this Notice of Annual General Meeting. The additional disclosures for this resolution required by ASX Listing Rule 10.17 are set out at Item 5 of the Explanatory Notes attached to this Notice of Annual General Meeting.

By order of the Board

A handwritten signature in black ink that reads "Ray Jarman". The signature is written in a cursive, slightly stylized font.

Ray Jarman

Company Secretary

Dated: 8 September 2017

Item 1. Financial and other reports

As required by section 317 of the Corporations Act 2001 (Cth) (Act), the Company's Financial Report, the Directors' Report and the Auditor's Report for the financial year ended 30 June 2017 (FY17) will be laid before the Company in the Annual General Meeting (AGM). There is no requirement for a formal resolution on this item; however, it is the Company's practice to do so.

Resolution 1.1 – directors' recommendation

The Board recommends that shareholders vote in favour of the resolution.

The Chairman intends to vote all available proxies in favour of the resolution.

Item 2. Remuneration Report

As required by section 250R(2) of the Act, the Remuneration Report of the Company for FY17 will be laid before the Company in the AGM and a resolution that it be adopted will be put to a vote. The Remuneration Report is set out in the Directors' Report contained in the Company's 2017 Annual Report. The Annual Report is available on the Company's website (www.cochlear.com).

The Remuneration Report explains the structure of and policy behind the Company's remuneration practices and the link between the remuneration of executives and the Company's performance. The Remuneration Report also sets out remuneration details for each director and for certain specified executives. A reasonable opportunity will be provided for discussion of the Remuneration Report at the meeting. Although there is a requirement for a formal resolution on this item, by operation of section 250R(3) of the Act, the resolution is advisory only and does not bind the directors or the Company.

The Board believes Cochlear's approach to Board and executive KMP remuneration is a balanced, fair and equitable approach. The Company's executive remuneration practices are designed to reward and motivate a successful and experienced executive team to deliver ongoing business growth which meets the expectations of all shareholders. The Board welcomes feedback from shareholders on Cochlear's remuneration practices.

Resolution 2.1 – directors' recommendation

The Board recommends that shareholders vote in favour of the resolution.

Voting exclusions apply to this resolution as specified in the Notice of Annual General Meeting.

The Chairman intends to vote all available proxies in favour of the resolution.

Item 3. Re-election of directors

Pursuant to Article 15.5(a) of the Company's Constitution, the directors have the power to appoint any person as a director, either to fill a casual vacancy or as an addition to the directors. Article 15.5(b) requires that any person appointed as a director pursuant to Article 15.5(a) (excluding the Company's Chief Executive Officer & President (CEO&P)) will retire at the next following AGM of the Company and will then be eligible for re-election as a director. Prof Bruce Robinson, AM was appointed by the Board as a director of the Company with effect from 13 December 2016. Accordingly, Prof Bruce Robinson, AM is retiring at this AGM and is standing for re-election.

Pursuant to Article 16.2 of the Company's Constitution, each director (excluding the CEO&P) must retire from office not later than at the third AGM following his or her last election or appointment by a general meeting, but may submit himself or herself for and will be eligible for re-election. Mr Andrew Denver and Mr Rick Holliday-Smith are retiring at this AGM in accordance with Article 16.2.

The retirements of Mr Andrew Denver, Mr Rick Holliday-Smith and Prof Bruce Robinson, AM mean that the requirement of Article 16.1 of the Company's Constitution, that one-third of the directors for the time being (excluding the CEO&P and rounded down to the nearest multiple of 3) retire from office at each AGM, is also satisfied.

The Board considers that each of Mr Andrew Denver, Mr Rick Holliday-Smith and Prof Bruce Robinson, AM is an independent non-executive director.

Mr Andrew Denver
Non-executive Director
Age 68

BSc (Hons), MBA,
FAICD



Appointed to the Board 1 February 2007; Chairman of the Technology & Innovation Committee. Member of the Audit, Medical Science and Nomination Committees.

Background: Extensive experience in the life sciences industry. Former director of Principals Cornerstone Management Pty Limited. Former Managing Director of Memtec Limited and President Asia for Pall Corporation.

Other boards: Chairman, Speedx Pty Ltd and Director, Vaxxas and QBiotics.

Resolution 3.1 – directors' recommendation

The Board (other than Mr Andrew Denver) recommends that shareholders vote in favour of the resolution.

The Chairman intends to vote all available proxies in favour of the resolution.

Mr Rick Holliday-Smith
Chairman
Age 67



BA (Hons), FAICD, CA

Appointed to the Board 1 March 2005; Chairman of the Board and Nomination Committee. Member of the Audit and People & Culture Committees.

Background: Global executive and leadership experience in capital markets and derivatives, and a background in venture capital activities. Former President of NationsBank-CRT, Chicago and Managing Director of Hong Kong Bank Limited, London.

Other boards: Chairman, ASX Limited and Director, Servcorp Limited. Non-executive Chairman, QBiotics and member of the Macquarie University Faculty of Business and Economics Advisory Board.

Former directorships: Chairman, Snowy Hydro Limited and SFE Corporation Limited. Director, St George Bank Limited, Exco Resources NL, DCA Group Limited and MIA Group Limited.

Resolution 3.2 – directors' recommendation

The Board (other than Mr Rick Holliday-Smith) recommends that shareholders vote in favour of the resolution.

The Chairman intends to vote all available proxies in favour of the resolution.

Prof Bruce Robinson, AM
Non-executive Director
Age 60



MD, MSc, FRACP,
FAAHMS, FAICD

Appointed to the Board 13 December 2016; Member of the Medical Science, Nomination, People & Culture and Technology & Innovation Committees.

Background: Over 20 years' leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. Former Dean, The University of Sydney's Sydney Medical School, Head of Medicine at Sydney's Royal North Shore Hospital and Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research.

Other boards: Chairman, National Health and Medical Research Council and Medical Benefits Schedule Review Taskforce. Director, MaynePharma, Firefly and QBiotics.

Resolution 3.3 – directors' recommendation

The Board (other than Prof Bruce Robinson, AM) recommends that shareholders vote in favour of the resolution.

The Chairman intends to vote all available proxies in favour of the resolution.

Item 4. Approval of securities to be granted to the President under the Cochlear Executive Incentive Plan

Why is shareholder approval being sought?

Mr Howitt was appointed as the President of the Company on 31 July 2017 and will become CEO&P of the Company when the existing Chief Executive Officer Mr Smith retires on 2 January 2018.

While Mr Howitt is not currently a director of the Company and will not become the CEO&P until 3 January 2018, the Company intends to seek approval for the grant of Cochlear Executive Incentive Plan long-term incentive awards (CEIP LTI) to Mr Howitt, as it is the Company's practice to do so for the CEO&P and for good corporate governance.

Terms of the CEIP LTI

Purpose: The CEIP LTI is designed to reward participants for the long-term growth of the Company.

Structure: For the financial year ending 30 June 2018 (FY18), participants can elect to receive options alone, or a combination of performance rights (being rights to subscribe for or be allocated or receive the transfer of ordinary shares in the Company) and options, provided as a minimum at least 30% are options.

Mr Dig Howitt has elected to receive 70% of his FY18 offer as options and 30% of his FY18 offer as performance rights. The CEIP rules permit the Company to satisfy its obligation to deliver shares under options or performance rights through an employee share trust.

Each option or performance right entitles Mr Howitt to receive the transfer of one ordinary share in the capital of the Company, subject to certain vesting restrictions.

Approval is being sought from shareholders for the FY18 grant of options and performance rights to Mr Howitt under the CEIP LTI. If shareholders approve the grant of options and performance rights to Mr Howitt in accordance with the proposed resolution, the Company will issue the options and performance rights within five (5) business days of the Company's 2017 AGM. These options and performance rights will be taken to be granted as at 18 October 2017, being the date on which CEIP LTI options and/or performance rights will be granted to other Company executives under the CEIP (based on values determined as at 23 August 2017).

The options will be granted for nil consideration with an exercise price of A\$154.73, being the weighted average price of ordinary shares in the Company traded on the ASX during the five day period commencing on the release of the Company's FY17 full year results on 17 August 2017, payable on exercise of the options.

Performance rights are granted for nil consideration with a nil exercise price.

Vesting restrictions: The options and performance rights are subject to vesting restrictions, which will ultimately determine the final number of options and performance rights which will be exercisable. The relevant vesting restrictions for the FY18 offers are:

(i) the options and performance rights will not vest before the full year results are announced in 2020. The participant will be unable to exercise the options and performance rights before they vest unless the Board decides to allow early exercise pursuant to the CEIP rules. Should the participant cease to be an employee of Cochlear or a related body corporate, all unvested options and performance rights will lapse unless the Board determines otherwise; and

(ii) the performance of the Company from 1 July 2017 to 30 June 2020 in terms of annual growth in earnings per share (EPS) and in terms of total shareholder return (TSR) as measured against the S&P/ASX 100 comparator group, each according to the table set out below. Half of the offer will be assessed against EPS growth and the other half using TSR as follows:

Compound annual growth rate of EPS over the three year vesting period		Ranking of TSR against S&P/ASX 100 comparator group over the three year vesting period	
Performance	% vesting	Performance	% vesting
< 10%	0%	< 50 th percentile	0%
10% to 20%	50% to 100% (pro-rata)	50 th to 75 th percentile	40% to 100% (pro-rata)
> 20%	100%	> 75 th percentile	100%

Calculation of the number of securities relating to be granted to Mr Howitt under the CEIP LTI for FY18

Assumptions:

Based on Mr Howitt's remuneration, his role and the Company's remuneration strategy, the value of the offer is A\$1,600,000.

(a) The value of an option is defined below and is A\$23.91. The value of a performance right is defined below and is A\$142.31.

(b) Options and performance rights are subject to the EPS and TSR vesting hurdles described above.

Total value of offer (TVO)	A\$1,600,000
Components	Options and performance rights
Option value (OV)	A\$23.91
Performance right value (PV)	A\$142.31
Number of options and performance rights	$= \frac{TVO \times 70\%}{OV} + \frac{TVO \times 30\%}{PV}$ $= \frac{A\$1,120,000}{A\$23.91} + \frac{A\$480,000}{A\$142.31}$ $= 46,842 \text{ options and } 3,372 \text{ performance rights}$

where:

TVO = the total value of the offer made to the participant under the CEIP LTI (expressed in Australian dollars), which is a percentage of fixed remuneration of the participant;

OV = the value of an option, based on the Black-Scholes-Merton value before service or EPS and TSR performance discounts; and

PV = the value of a performance right, based on the Black-Scholes-Merton value before service or EPS and TSR performance discounts.

Exercise price (options)	A\$154.73
Exercise price (performance rights)	Nil
Expected volatility	24.91%
Expected contract life (options)	3.43 years
Expected contract life (performance rights)	2.93 years
Expected dividend yield	2.95%
Risk free interest rate	2.00%

Other terms of the CEIP

Eligibility: Persons who are permanent full-time or part-time employees of the Company or a related body corporate of the Company are Eligible Employees.

Allocation: The CEIP is administered by the Board. Each year, the Board may decide to offer designated Eligible Employees the opportunity to participate in the CEIP. The number of options and/or performance rights to be offered to a participant depends upon the participant's salary and the Company's target remuneration package for the participant's position.

The Board has determined that any options or performance rights that do not vest will lapse or be forfeited automatically.

Rights: Option and performance right holders will not be entitled to any dividend payments until the options or performance rights are exercised.

Additional conditions: All participants will be bound by the applicable plan rules. A participant must exercise their options within seven months after the date of vesting, otherwise the options will lapse. Performance rights will be exercised automatically on vesting. The shares delivered on exercise of options or performance rights will be held by an employee share trust until withdrawn by participants. While participants are employees of the Company, they must abide by the Company's Trading Policy (available in the Investor Centre section of www.cochlear.com under Corporate Governance).

It is a specific condition of grant that no schemes are entered into by an individual or their associates that specifically protect the unvested value of options or performance rights allocated.

The CEIP requires that any shares to be delivered to a director upon the exercise of options or performance rights that are issued under the CEIP after 21 July 2015 must be existing shares acquired on market.

Plan limit: An overall limit applies on the number of options and performance rights that are offered under the CEIP, being that the aggregate of the number of options and performance rights offered together with outstanding offers under the CEIP and the total number of shares issued to employees under employee incentive schemes in the last five years cannot exceed 5%, excluding unregulated offers, of the total number of issued shares at the time of the offer.

Overriding restrictions: No options or performance rights may be offered under the CEIP if to do so would contravene the Act, the ASX Listing Rules, or instruments of relief issued by the Australian Securities and Investments Commission from time to time relating to the CEIP or employee incentive schemes generally.

Administration: The Board may amend, terminate or suspend the operation of the CEIP and/or any relevant CEIP rules at any time.

Resolution 4.1 – directors’ recommendation

The Board recommends that shareholders vote in favour of the resolution.

Voting exclusions apply to this resolution as specified in the Notice of Annual General Meeting.

The Chairman intends to vote all available proxies in favour of the resolution.

Item 5. Approval to increase the maximum aggregate remuneration of non-executive directors

In accordance with ASX Listing Rule 10.17 and Article 19.1 of the Company's Constitution, this resolution is being put to shareholders to increase the maximum aggregate amount available for the remuneration of non-executive directors (NED Fee Cap) by \$500,000 to \$3,000,000 per financial year.

The current NED Fee Cap of \$2,500,000 per financial year was approved by the shareholders at the 2015 Annual General Meeting. The temporary increase of \$500,000 approved at the 2014 AGM was solely to permit payment to Prof Edward Byrne, AC of his retirement allowance in the financial year in which he retires.

The present increase is being sought because the Board has recently increased in size by one non-executive director and it is anticipated that an additional Board appointment may be made in FY18 to increase the diversity of membership on the Board. This appointment would increase the number of non-executive directors to nine. Any new appointment would be subject to election by shareholders at the following AGM.

The Board also wishes to allow for future increases in fees to maintain market competitiveness to retain and attract high calibre non-executive directors and to reflect increasing demands on non-executive directors due to the expanding, complex and global nature of the Company's business. The level of non-executive directors' fees is reviewed annually for alignment with market competitiveness. In considering non-executive directors' fees, the Board seeks the advice of an independent remuneration consultant to ensure the Company's approach is appropriate.

Details of the non-executive director remuneration for the financial year ended 30 June 2017 are included in the 2017 Remuneration Report which forms part of the Directors' Report. The total aggregate value of remuneration provided to non-executive directors during the last financial year was \$2,063,703.

It is not intended to fully utilise the increase in the NED Fee Cap now, but to allow the flexibility to appoint an additional non-executive director and adequately compensate the Company's non-executive directors in the future.

Additional disclosures required by ASX Listing Rule 10.17

ASX Listing Rule 10.17 requires the following additional disclosures for the purposes of Item 5 of these Explanatory Notes:

- (i) if this resolution is passed, the maximum aggregate amount of directors' fees that may be paid to all of the Company's non-executive directors in a financial year is \$3,000,000, except that in the financial year in which Prof Edward Byrne, AC retires as a director of the Company, the maximum aggregate amount of directors' fees that may be paid to all of the Company's non-executive directors will be \$3,500,000 (as approved by shareholders at the 2014 AGM), and the maximum aggregate directors' fees will revert back to \$3,000,000 in the following financial year; and
- (ii) no securities have been issued to a non-executive director under ASX Listing Rule 10.11 or 10.14 within the preceding three years.

Resolution 5.1 – directors' recommendation

As each non-executive director has an interest in this matter, the Board does not believe it is appropriate to make a recommendation to shareholders in relation to voting on this resolution.

Voting exclusions apply to this resolution as specified in the Notice of Annual General Meeting.

The Chairman intends to vote all available proxies in favour of the resolution.

Quorum, who may vote and proxies

Quorum

The Company's Constitution provides that two registered Company shareholders present personally or by representative, attorney or proxy shall be a quorum for a general meeting of the Company.

Who may vote

Persons whose names are set out in the register of shareholders as at 10:00am (AEDT) on Sunday 15 October 2017 are entitled to attend and vote at the AGM (and at any adjournment of the meeting which takes place within 28 days).

Proxies

If you wish to appoint a proxy, you should complete the enclosed proxy/voting form and comply with the details set out in that form for lodgement. A proxy need not be a shareholder of the Company. The proxy/voting form must be received not less than 48 hours before the time for holding the AGM. Documents may be lodged using the reply paid envelope or by posting or facsimile to:

Cochlear Limited Share Registry
Computershare Investor Services Pty Limited
GPO Box 242 Melbourne VIC 3001
Australia
Facsimile 03 9473 2555

Number of proxies

A shareholder of the Company who is entitled to attend and cast a vote at a meeting has a right to appoint a single proxy. A shareholder of the Company who is entitled to attend and cast two or more votes at a meeting has a right to appoint up to two proxies. If you wish to appoint two proxies, please contact the Company's Share Registry for another proxy/voting form or copy the proxy/voting form and follow the directions as to how to complete the two proxy/voting forms.

Proportion of votes per proxy

Where the appointment is for more than one proxy, it may specify the proportion of votes that the proxy may exercise. If the appointment does not specify the proportion of votes that each proxy may exercise, then each proxy may exercise half of the votes of the relevant member.

Voting

Unless the member specifically directs the proxy how to vote, the proxy may vote as he or she thinks fit (except as specified in the Voting Exclusion Statements in the Notice of AGM) or abstain from voting.

Signing of proxy/voting form

The proxy/voting form must be signed as follows:

Individual: Where the holding is in one name, the shareholder must sign;

Joint holding: Where the holding is in more than one name, all of the shareholders must sign;

Power of attorney: To sign under power of attorney, you must have already lodged this document with the Company's Share Registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the power of attorney to the proxy/voting form when you return it; or

Companies: Where a company has a sole director who is also the sole company secretary, the proxy/voting form must be signed by that person. If a company (pursuant to section 204A of the Act) does not have a company secretary, a sole director can also sign alone. Otherwise, the proxy/voting form must be signed by a director jointly with either another director or a company secretary. Please indicate the office by signing in the appropriate place.

Shareholder questions

If you would like a question to be put to the Chair of the meeting or the auditor and you are not able to attend the meeting, please complete the Questions from Shareholders form enclosed and send it to:

Company Secretary
Cochlear Limited
1 University Avenue
Macquarie University NSW 2109
Australia

Alternatively, email it to the Company Secretary at:
rjarman@cochlear.com

Questions must be received by the Company Secretary by 5:00pm (AEDT) on Wednesday 11 October 2017.

Hear now. And always

As the global leader in implantable hearing solutions, Cochlear is dedicated to bringing the gift of sound to people with moderate to profound hearing loss. We have helped over 450,000 people of all ages live full and active lives by reconnecting them with family, friends and community.

We aim to give our recipients the best lifelong hearing experience and access to innovative future technologies. For our professional partners, we offer the industry's largest clinical, research and support networks.

That's why more people choose Cochlear than any other hearing implant company.

 Cochlear Ltd (ABN 96 002 618 073) 1 University Avenue, Macquarie University, NSW 2109, Australia T: +61 2 9428 6555 F: +61 2 9428 6352

www.cochlear.com

Please seek advice from your medical practitioner or health professional about treatments for hearing loss. They will be able to advise you on a suitable solution for your hearing loss condition. All products should be used only as directed by your medical practitioner or health professional.

Not all products are available in all countries. Please contact your local Cochlear representative.

ACE, Advance Off-Stylet, AOS, AutoNRT, Autosensitivity, Beam, Button, CareYourWay, Carina, Cochlear, Cochlear SoftWear, コクレア, Codacs, ConnectYourWay, Contour, Contour Advance, Custom Sound, ESPrit, Freedom, Hear now. And always, HearYourWay, Hugfit, Hybrid, inHear, Invisible Hearing, Kanso, MET, MicroDrive, MP3000, myCochlear, mySmartSound, NRT, Nucleus, 科利耳, Off-Stylet, Slimline, SmartSound, Softip, SPrint, True Wireless, the elliptical logo, WearYourWay and Whisper are either trademarks or registered trademarks of Cochlear Limited. Ardium, Baha, Baha SoftWear, BCDrive, DermaLock, EveryWear, Vistafix and WindShield are either trademarks or registered trademarks of Cochlear Bone Anchored Solutions AB.

© Cochlear Limited 2017. D1274785 ISS1 AUG17

